Filgrastim (Granulocyte Colony-Stimulating Factor, G-CSF)(fill grass’ stim)
Neupogen
PREGNANCY CATEGORY C
Drug Class
Colony-stimulating factor
Therapeutic Actions
Human granulocyte colony-stimulating factor produced by recombinant DNA technology; increases the production of neutrophils within the bone marrow with little effect on the production of other hematopoietic cells.
Indications
To decrease the incidence of infection in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a significant incidence of severe neutropenia with fever
To reduce the time to neutrophil recovery and duration of fever, following induction or consolidation chemotherapy treatment
of acute myeloid leukemia
To reduce the duration of neutropenia following bone marrow transplant
Treatment of severe chronic neutropenia
Mobilization of hematopoietic progenitor cells into the blood for leukapheresis collection
Orphan drug uses: Treatment of myelodysplastic syndrome, aplastic anemia, graft failure after bone marrow transplant, hairy cell leukemia, AIDS–drug-induced neutropenias, neutropenic fever
Contraindications and Cautions
Contraindicated with hypersensitivity to Escherichia coli products.
Use cautiously with lactation, pregnancy.
Available Forms
Injection—300 mcg/mL, 480 mcg/1.6 mL; prefilled syringes—300 mcg/0.5 mL, 480 mcg/0.8 mL.
Dosages
Adults
Starting dose is 5 mcg/kg/day subcutaneously or IV as a single daily injection. May be increased in increments of 5 mcg/kg for each chemotherapy cycle; 4–8 mcg/kg/day is usually effective.
Bone marrow transplant: 10 mcg/kg/day IV or continuous subcutaneous infusion.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
